ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYH2082

A development code. Also written as “SYH2082 Injection”.

Its studies are mostly in Obesity, led by CSPC Pharmaceutical Group.

Furthest: phase 1, since Apr 2, 20262 company-led studies, 2 open or runningNext primary completion: Jan 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 1since Apr 2, 2026Apr 2, 2026Jan 30, 2027phase 1 · NCT07532655

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2026First study: phase 1 study in OverweightFirst studyNCT07532655 · 60 planned · Australia
  2. Jul 14, 2026Phase 1 study in OverweightNCT07736404 · 50 enrolled · China
  3. Oct 23, 2026Primary completion moved from 2026-10-28 to 2027-01-30Date moved laterphase 1 · +3 months · NCT07532655

Ahead

  1. Jan 30, 2027Primary completion: phase 1 study in OverweightNCT07532655

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07736404Overweight · China1Active, not recruitingSep 30, 202650
NCT07532655Overweight · Australia1RecruitingJan 30, 202760

How it is read

Names in the registry

  • “SYH2082 Injection”, 2 entries

Codes read as this program: SYH2082.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.